 VolitionRx NYSE-A:VNRX Limited has inked a pair of research and development collaborations that will develop targeted, adoptive cell therapies to treat cancer and help advance a drug designed to treat solid and hematologic cancers. First off, the company will collaborate with Xenetic Biosciences NASDAQ:XBIO Inc to evaluate the potential combination of Volitions Nu.Q NETs Test and Xenetics DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting multiple types of solid cancers. 